PRO APARTS

Pro Aparts is a pharmaceutical research and development company based in Madeira, Portugal, specializing in therapies for cardiovascular and infectious diseases. The company is best known for its development of high-purity omega-3 fatty acid compositions, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), aimed at the primary prevention of cardiovascular mortality and heart failure. Pro Aparts also advanced SPK-843, a semi-synthetic polyene antifungal derivative of partricin, into Phase 3 clinical trials for the treatment of pulmonary mycosis. Additionally, the company's research portfolio includes the development of lipase inhibitors for the management of obesity and metabolic disorders. Pro Aparts maintains a significant international patent estate and has been a key participant in intellectual property developments within the lipid therapy sector.